Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N06DA03

Exelon(rivastigmine)

Dementia;Alzheimer Disease;Parkinson Disease

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 11/05/1998

INN: rivastigmine

Indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Exelon — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.